CHRS · Coherus Oncology, Inc.
$1.47
+0.05 (+3.52%)
At close · Jul 21
Market Cap
$226.75M
Shares
154.25M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$42.17M
+59.8%
FY2025
Net Income
$168.02M
+489.4%
FY2025
Gross Margin
67.24%
+0.3pp
FY2025
Operating Margin
-429.51%
+327.1pp
FY2025
Diluted EPS
$1.43
+472%
FY2025
Operating Cash Flow
-$138.51M
-577.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2028 (G) | FY2027 (G) | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $175M | $30M – $35M | $15M – $16M | $46.88M | $42.17M | $26.39M | $257.24M | $211.04M | $326.55M | $475.82M | $356.07M | $0 | $1.56M | $190.11M | $30.04M | $31.11M | $2.75M | $1.9M | |
| — | — | — | $14.98M | $13.81M | $8.73M | $158.99M | $70.08M | $57.59M | $37.67M | $17.08M | — | — | — | — | — | — | — | |
| — | — | — | $31.91M | $28.36M | $17.66M | $98.25M | $140.96M | $268.96M | $438.16M | $338.99M | — | — | — | — | — | — | — | |
| — | — | — | — | 67.24% | 66.93% | 38.19% | 66.79% | 82.36% | 92.08% | 95.2% | — | — | — | — | — | — | — | |
| — | — | — | $106.08M | $108.89M | $91.83M | $109.44M | $199.36M | $363.11M | $142.76M | $94.19M | $110.24M | $162.39M | $254.44M | $213.06M | $78.22M | $31.28M | $34.89M | |
| — | — | — | $75.32M | — | — | — | — | — | — | — | — | $71.3M | $51.6M | $36.05M | $17.56M | $7.47M | $5.53M | |
| — | — | — | $97.68M | $100.6M | $125.48M | $192.02M | $198.48M | $169.71M | $139.08M | $137.04M | $94.18M | $71.3M | $51.6M | — | — | — | — | |
| — | — | — | $2.5M | $2.6M | $3.4M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | $1.14M | $1.3M | $1.6M | $3.2M | $3.6M | $3.5M | $2.89M | $3.26M | $3.24M | $3.4M | $3M | $1.87M | $674K | $404K | $221K | |
| — | — | — | — | — | — | — | — | — | — | — | $3.6M | $3.6M | — | — | — | — | — | |
| — | — | — | $304.33M | — | — | — | — | — | — | $248.3M | $204.42M | $233.69M | $306.04M | $249.11M | $95.79M | $38.74M | $40.42M | |
| — | — | — | $218.73M | $223.31M | $226.04M | $460.44M | $467.92M | $590.41M | $319.51M | $248.3M | $204.42M | — | — | — | — | — | — | |
| — | — | — | -$171.85M | -$181.13M | -$199.65M | -$203.2M | -$256.88M | -$263.86M | $156.32M | $107.77M | -$204.42M | -$232.14M | -$115.93M | -$219.07M | -$64.68M | -$35.99M | -$38.52M | |
| — | — | — | — | -429.51% | -756.58% | -78.99% | -121.72% | -80.8% | 32.85% | 30.27% | — | -14918.77% | -60.98% | -729.23% | -207.94% | -1308.36% | -2028.33% | |
| — | — | — | -$170.72M | -$179.83M | -$198.05M | -$200M | -$253.28M | -$260.36M | $159.21M | $111.03M | -$201.18M | -$228.74M | -$112.94M | -$217.2M | -$64.01M | -$35.59M | -$38.3M | |
| — | — | — | $9.04M | $9M | $10.73M | $40.54M | $32.47M | $22.96M | $21.17M | $17.6M | $9.68M | $9.55M | $7.98M | $33K | $3.9M | $5.29M | $1.51M | |
| — | — | — | — | $7M | $4.5M | $2.8M | $1.9M | $1.4M | $600K | $1.6M | $1.4M | — | — | — | — | — | — | |
| — | — | — | $8.23M | $7.01M | $7.62M | $5.47M | $3.82M | -$283K | $554K | $2.61M | $4.69M | $3.4M | -$3.88M | -$4.84M | -$18.6M | -$12.35M | $7.01M | |
| — | — | — | -$172.66M | -$183.12M | -$215.39M | -$238.27M | -$291.75M | -$287.1M | $135.71M | $92.78M | -$209.41M | -$238.29M | — | — | — | — | — | |
| — | — | — | — | $0 | $0 | -$380K | $0 | $0 | $3.46M | $2.94M | $0 | $0 | $0 | $0 | $0 | — | — | |
| — | — | — | $186.27M | $168.02M | $28.51M | -$237.89M | -$291.75M | -$287.1M | $132.24M | $89.83M | -$209.34M | -$238.17M | -$127.34M | -$223.26M | -$87.13M | -$53.64M | -$33.02M | |
| — | — | — | — | 398.43% | 108.03% | -92.48% | -138.24% | -87.92% | 27.79% | 25.23% | — | -15306.56% | -66.98% | -743.18% | -280.12% | -1949.65% | -1738.7% | |
| — | — | — | — | — | — | — | — | — | — | $0 | -$70K | -$116K | -$451K | -$678K | -$44K | — | — | |
| — | — | — | — | — | — | — | — | — | $132.53M | $89.56M | -$208.87M | -$238.29M | -$127.57M | -$223.14M | -$87.66M | -$53.64M | -$33.02M | |
| USD/shares | — | — | — | — | $1.43 | $0.25 | -$2.53 | -$3.76 | -$3.81 | $1.85 | $1.29 | -$3.22 | -$4.48 | — | — | — | — | — |
| USD/shares | — | — | — | — | $1.43 | $0.25 | -$2.53 | -$3.76 | -$3.81 | $1.62 | $1.23 | -$3.22 | -$4.48 | — | — | — | — | — |
| shares | — | — | — | — | 117.14M | 114.55M | 94.16M | 77.63M | 75.45M | 71.41M | 69.68M | 65.03M | 53.13M | 41.91M | 37.13M | 8.52M | 4.83M | 4.96M |
| shares | — | — | — | — | 117.14M | 114.55M | 94.16M | 77.63M | 75.45M | 83.49M | 73.19M | 65.03M | 53.13M | 41.91M | 37.12M | 8.19M | 3.33M | 2.08M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.46×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
0.90×
Biotechnology median 7.03×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2019 | FY2018 | FY2017 |
|---|---|---|---|
| United States | $356,071,000 | $0 | $0 |
| Non Us | $0 | $0 | $1,556,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Toripalimab | $40,836,000 | $19,131,000 | $554,000 | — | — | — | — | — |
| Product And Service Other | $1,336,000 | $7,258,000 | $664,000 | $282,000 | $42,000 | — | — | — |
| Cimerli | — | — | $125,388,000 | $6,946,000 | — | — | — | — |
| Udenyca | — | — | $127,064,000 | $203,814,000 | $326,509,000 | $475,824,000 | — | — |
| Yusimry | — | — | $3,574,000 | — | — | — | — | — |
| License And Service | — | — | — | — | — | — | — | $0 |
| Product | — | — | $256,580,000 | $210,760,000 | $326,509,000 | — | $356,100,000 | $0 |
Key facts
CIK
1512762
CUSIP
19249H103
13F (30d)
11 filings
11 filers
Visit website
Investor relations